Janku Filip 4

What Happened Janku Filip, Chief Medical Officer of Monte Rosa Therapeutics (GLUE), exercised options to acquire 6,000 shares at $7.56 per share (cost $45,360) and sold those 6,000 shares in the open market the same day at $22.95 per share for total proceeds of $137,700 (gross net ~ $92,340 before taxes/fees). The filing also shows the corresponding derivative (the option) was extinguished on exercise.

Key Details

• Transaction date: 2026-06-29 (reported on Form 4 filed 2026-06-30).
• Exercise: 6,000 shares acquired at $7.56 each = $45,360 (Transaction code M).
• Sale: 6,000 shares sold at $22.95 each = $137,700 (Transaction code S).
• Derivative disposition: 6,000 option instruments removed upon exercise (listed at $0.00).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: F1 — trades were effected under a Rule 10b5-1 trading plan adopted March 4, 2026; F2 — the option shares were fully vested and exercisable.
• Timeliness: Form 4 was filed the day after the transactions; no late filing indicated.

Context This was an option exercise followed by an immediate open‑market sale of the exercised shares (common pattern often executed under prearranged 10b5‑1 plans). The 10b5‑1 plan note means the sale was part of a preplanned trading arrangement rather than a spontaneous market-timing decision.